Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

NEXT STORY
Neovasc REDUCER-I Study Published in EuroIntervention Journal
PREV STORY
Immunohistochemistry Market Size to Outstrip $3,585.31Mn by 2028 Growth Projections at 7.4% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems

author_avatar
NASDAQ Market News

MPI and OV enters exclusivity and ownership agreements of SPVs – financing secured for the first two SPVs

Hoersholm, Denmark, December 30th, 2016 - Medical Prognosis Institute (MPI.ST) and Oncology Venture Sweden ...

author_avatar
NASDAQ Market News

It’s Time To Look At UV-C Light Air Purification To Combat COVID-19 More Seriously – UPDATE

author_avatar
NASDAQ Market News